In lipid metabolism, inhibition of fatty acid oxidation (e.g., with the CPT1 inhibitor etomoxir) was shown to synergize with CD47-blocking antibodies and radiotherapy to enhance anti-tumor effects in a mouse glioblastoma (GBM) model (98). This evidence concerns the gene CD47 and glioblastoma.